Table 3 The association between the methylation and the clinicopathological features of UC patients.
Urothelial carcinoma(n = 135) | ||||
|---|---|---|---|---|
Overall | Positive | Negative | P value | |
Age/year (Median(range)) | 68 (31–91) | 65 (33–91) | 66 (31–83) | |
Gender | ||||
Male (%) | 110 (81.5%) | 90 (78.3%) | 20 (100%) | 0.0245# |
Female (%) | 25 (18.5%) | 25 (21.7%) | 0 (0%) | |
WHO 2004/2016 | ||||
Low grade | 20 (14.8%) | 16 (13.9%) | 4 (20.0%) | < 0.0001 |
High grade | 105 (77.8%) | 97 (84.3%) | 8 (40.0%) | |
Low/non-malignant potential | 10 (7.4%) | 2 (1.7%) | 8 (40.0%) | |
TNM Stage | ||||
0 | 13 (9.6%) | 12 (10.4%) | 2 (10.0%) | 0.2682 |
I | 50 (37.0%) | 66 (57.4%) | 16 (80.0%) | |
II | 52 (38.5%) | 17 (14.8%) | 2 (10.0%) | |
III | 10 (7.4%) | 10 (8.7%) | 0 (0%) | |
IV | 10 (7.4%) | 10 (8.7%) | 0 (0%) | |
T Stage | ||||
Ta | 13 (9.6%) | 11 (9.6%) | 2 (10%) | 0.2967$ |
Tis | 0 (0%) | 0 (0%) | 0 (0%) | |
T1 | 50 (37.0%) | 67 (58.3%) | 16 (80.0%) | |
T2 | 54 (40.0%) | 19 (16.5%) | 2 (10.0%) | |
T3 | 11 (8.1%) | 11 (9.6%) | 0 (0%) | |
T4 | 7 (5.2%) | 7 (6.1%) | 0 (0%) | |
Invasiveness | ||||
Non-invasive | 50 (37.0%) | 35 (30.4%) | 15 (75.0%) | 0.0074# |
Invasive | 85 (63.0%) | 80 (69.6%) | 5 (25.0%) | |
